MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
🚨
Price Alert:
The stock price dropped by 23.04% after the earning call.
Show more
Cash Flow Overview
Change in Cash
-$2,941K
Free Cash flow
$292,044K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sales and maturities of marketab...
Net income (loss)
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Prepaid expenses and other asset...
Purchases of property, plant and...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
164,494
205,991
186,419
251,084
Depreciation and amortization
13,899
13,553
13,506
13,803
Non-cash interest expense on liabilities related to the sale of future royalties and development funding
79,043
66,236
126,101
40,864
Stock-based compensation expense
86,625
70,154
71,632
108,211
Realized and unrealized loss on marketable equity securities
0
0
0
0
Loss related to convertible debt
-
-
-3,327
-39,146
Change in fair value of development derivative liability
-
-
138,813
-64,663
Deferred income taxes
2,657
9,310
-27,170
5,598
Other
8,278
2,994
1,706
6,400
Accounts receivable, net
31,602
110,421
-184,247
399,863
Inventory
-280
3,324
13,861
-4,976
Prepaid expenses and other assets
59,369
6,323
70,990
20,742
Accounts payable, accrued expenses and other liabilities
61,617
-176,033
-174,854
223,509
Deferred revenue
802
-1,633
2,305
-12,540
Net cash provided by operating activities
326,724
70,504
163,555
325,109
Purchases of property, plant and equipment
34,680
21,833
23,292
12,142
Purchases of marketable securities
575,672
261,625
235,911
207,971
Sales and maturities of marketable securities
272,795
213,191
222,037
723,370
Proceeds from maturity of restricted and other investments
17,900
48,825
0
1,700
Purchases of restricted and other investments
17,900
4,100
0
1,700
Other investing activities
25,900
-
0
2,150
Net cash used in investing activities
-363,457
-25,542
-37,166
501,107
Proceeds from issuance of 0.00 convertible senior notes due 2028, net
-
-
-680
646,372
Purchases of capped calls related to 0.00 convertible senior notes due 2028
-
-
0
35,311
Repayment of 1.00 convertible senior notes due 2027
-
-
52,254
1,102,659
Payment of issuance costs for revolving credit agreement
-
-
0
2,414
Proceeds from exercise of stock options and other types of equity, net
33,561
13,157
41,701
77,740
Proceeds from liabilities related to the sale of future royalties and development funding
6,000
6,000
6,000
-
Repayment of liabilities related to the sale of future royalties and development funding
3,318
3,434
14,272
-
(repayment of) proceeds from development derivative liability, net
-
-
-64,822
32,076
Other financing activities
-6
-9
-
-
Net cash provided by financing activities
36,237
15,714
45,317
-448,348
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-2,445
-7,064
-5,701
-927
Net increase in cash, cash equivalents and restricted cash
-2,941
53,612
166,005
376,941
Cash, cash equivalents and restricted cash, beginning of period
1,712,419
1,658,807
1,022,249
1,022,249
Cash, cash equivalents and restricted cash, end of period
1,709,478
1,712,419
1,658,807
1,492,802
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income (loss)
$164,494K
(348.19%↑ Y/Y)
Stock-based compensation
expense
$86,625K
(-22.43%↓ Y/Y)
Non-cash interest
expense on liabilities...
$79,043K
(116.72%↑ Y/Y)
Proceeds from exercise of
stock options and...
$33,561K
(-58.68%↓ Y/Y)
Proceeds from
liabilities related to the...
$6,000K
Accounts payable,
accrued expenses and...
$61,617K
(-66.17%↓ Y/Y)
Depreciation and
amortization
$13,899K
(-0.32%↓ Y/Y)
Other
$8,278K
(144.72%↑ Y/Y)
Deferred income taxes
$2,657K
(-72.71%↓ Y/Y)
Deferred revenue
$802K
(106.13%↑ Y/Y)
Inventory
-$280K
(97.49%↑ Y/Y)
Net cash provided by
operating activities
$326,724K
(112.53%↑ Y/Y)
Net cash provided by
financing activities
$36,237K
(-32.59%↓ Y/Y)
Canceled cashflow
$90,971K
Canceled cashflow
$3,324K
Net increase in
cash, cash...
-$2,941K
(-103.14%↓ Y/Y)
Canceled cashflow
$362,961K
Sales and maturities
of marketable...
$272,795K
(-17.95%↓ Y/Y)
Proceeds from maturity of
restricted and other...
$17,900K
(93.51%↑ Y/Y)
Prepaid expenses and
other assets
$59,369K
(976.04%↑ Y/Y)
Accounts receivable, net
$31,602K
(-76.92%↓ Y/Y)
Repayment of liabilities
related to the sale of...
$3,318K
Other financing
activities
-$6K
Net cash used in
investing activities
-$363,457K
(-157.08%↓ Y/Y)
Canceled cashflow
$290,695K
Effect of exchange rate
changes on cash, cash...
-$2,445K
(-108.89%↓ Y/Y)
Purchases of marketable
securities
$575,672K
(25.27%↑ Y/Y)
Purchases of property,
plant and equipment
$34,680K
(142.64%↑ Y/Y)
Other investing
activities
$25,900K
Purchases of restricted
and other...
$17,900K
(93.51%↑ Y/Y)
Buy us a coffee
logo (21)-svg-svg
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
logo (21)-svg-svg
ALNYLAM PHARMACEUTICALS, INC. (ALNY)